Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

i(22)(q10) in myeloid malignancies

Written2018-03Adriana Zamecnikova
Kuwait Cancer Control Center, Kuwait annaadria@yahoo.com

Abstract Isochromosome i(22)(q10) is a rare but non-random karyotypic change in hematologic malignancies, often associated with complex karyotypes and with partial or complete loss of chromosomes 5 and/or 7.

Keywords Isochromosome; chromosome 22.

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424
ICD-Morpho 9875/3
ICD-Morpho 9983/3 Refractory anaemia with excess blasts
ICD-Morpho 9989/3 Myelodysplastic syndrome, unclassifiable
ICD-Morpho 9874/3 AML with maturation
ICD-Morpho 9867/3 Acute myelomonocytic leukaemia
ICD-Morpho 9891/3 Acute monoblastic and monocytic leukaemia
ICD-Morpho 9840/3 Acute erythroid leukaemia
ICD-Morpho 9861/3 AML with mutated NPM1; AML with mutated CEBPA; Acute myeloid leukaemia, NOS
Atlas_Id 1819
 
  Partial karyotypes with i(22)(q10) (A). Fluorescence in situ hybridization with LSI BCR/ABL dual color probe revealing extra copy of the BCR gene on 22q11 as a result of isochromosome formation (Abott Molecular/Vysis, US) (B).

Clinics and Pathology

Disease Chronic and acute myeloid malignancies
Phenotype / cell stem origin Chronic myeloid malignancies in 7 (4 males and 3 females aged 59 to 73 years, median 68 years): refractory anemia with excess of blasts in 5 (Musilova & Michalova 1988; Geddes et al., 1990; Padua et al., 1998; Martinez-Ramirez et al., 2004; Lessard et al., 2007), 1 myelodysplastic syndrome (Andersen et al., 2005) and 1 chronic myeloid leukemia (Werner et al., 1991).
Acute myeloid leukemia in 16 (10 males and 6 females; median age 61 years; range 2-76 years): 5 with M2 (Berger et al., 1987; Van Limbergen et al., 2002; Rucker et al., 2006; Xu et al., 2008; ), 2 with M4 (Shurtleff et al., 1995; Johansson et al., 1997; Asou et al., 2009; ), 1 with M5 (Gervais et al., 2008), 1 with M6 (Bitter et al., 1985) and 7 with unspecified AML (Michels et al., 1989; Pedersen & Jensen; GFCH 1996; Morrison et al., 2002; Lugthart et al., 2010; Haferlach et al., 2012; Lavallee et al., 2015).
Epidemiology 23 patients (14 males, 9 females aged 2 to 76 years; median 63 years).
Prognosis The presence of i(22)(q10) in association with chromosome 5 and/or chromosome 7 anomalies in complex karyotypes is indicator of poor prognosis, representing a therapeutic challenge.

Cytogenetics

Note To exclude the possibility that der(22) chromosome contain two centromeres, use of centromere 22-specific FISH probes is recommended.
Cytogenetics Morphological Sole anomaly in 1 patient, loss of 5 and/or 7 chromosomal material seemed the most common event, and their losses in combination were observed in many cases: found with del(5q)/-5 in 4, with simultaneous del(5q)/del(7q) or del(7q)/-7 in 8 and with monosomy of both chromosomes in 2. Found as an additional anomaly to inv(16)(p13q22) in 2 and with miscellaneous or highly complex anomalies in the remaining patients.

Result of the chromosomal anomaly

Fusion Protein
Oncogenesis While trisomy 22 is a well know anomaly in myeloid leukemia, in particular, acute myelomonocytic leukemia with eosinophilia, i(22)(q10) is less common. The i(22q) formation leads to the gain of the entire long arm of chromosome 22 suggesting its possible role in oncogenesis. Gain of the whole long arm leads to overexpression of genes located on 22q due to a dosage effect. i(22)(q10) is mainly found as part of complex karyotypes, therefore may not be the primary disease determining aberration but rather a secondary event associated with disease evolution.
  

Bibliography

Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study
Andersen MK, Christiansen DH, Pedersen-Bjergaard J
Genes Chromosomes Cancer 2005 Apr;42(4):358-71
PMID 15645489
 
Identification of a common microdeletion cluster in 7q21
Asou H, Matsui H, Ozaki Y, Nagamachi A, Nakamura M, Aki D, Inaba T
3 subband among patients with myeloid leukemia and myelodysplastic syndrome Biochem Biophys Res Commun
PMID 19358830
 
Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias
Berger R, Flandrin G, Bernheim A, Le Coniat M, Vecchione D, Pacot A, Derré J, Daniel MT, Valensi F, Sigaux F, et al
Cancer Genet Cytogenet 1987 Nov;29(1):9-21
PMID 3478133
 
Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia
Bitter MA, Neilly ME, Le Beau MM, Pearson MG, Rowley JD
Blood 1985 Dec;66(6):1362-70
PMID 4063525
 
A report on 94 cases
Cytogenetic analysis in patients with primary myelodysplastic syndromes in leukaemic transformation
Groupe Français de Cytogénétique Hématologique (GFCH) Hematol Cell Ther
PMID 8931999
 
Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome
Geddes AA, Bowen DT, Jacobs A
Br J Haematol 1990 Oct;76(2):194-202
PMID 2094322
 
Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique
Gervais C, Murati A, Helias C, Struski S, Eischen A, Lippert E, Tigaud I, Penther D, Bastard C, Mugneret F, Poppe B, Speleman F, Talmant P, VanDen Akker J, Baranger L, Barin C, Luquet I, Nadal N, Nguyen-Khac F, Maarek O, Herens C, Sainty D, Flandrin G, Birnbaum D, Mozziconacci MJ, Lessard M; Groupe Francophone de Cytogénétique Hématologique
Leukemia 2008 Aug;22(8):1567-75
PMID 18528428
 
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events
Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger M, Kern W, Haferlach T
Genes Chromosomes Cancer 2012 Apr;51(4):328-37
PMID 22162288
 
Deletion of chromosome arm 3p in hematologic malignancies
Johansson B, Billström R, Kristoffersson U, Akerman M, Garwicz S, Ahlgren T, Malm C, Mitelman F
Leukemia 1997 Aug;11(8):1207-13
PMID 9264371
 
EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations
Lavallée VP, Gendron P, Lemieux S, D'Angelo G, Hébert J, Sauvageau G
Blood 2015 Jan 1;125(1):140-3
PMID 25331116
 
Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ? Cancer Genet Cytogenet
Lessard M, Hélias C, Struski S, Perrusson N, Uettwiller F, Mozziconacci MJ, Lafage-Pochitaloff M, Dastugue N, Terré C, Brizard F, Cornillet-Lefebvre P, Mugneret F, Barin C, Herry A, Luquet I, Desangles F, Michaux L, Verellen-Dumoulin C, Perrot C, Van den Akker J, Lespinasse J, Eclache V, Berger R; Groupe Francophone de Cytogénétique Hématologique
2007 Jul 1;176(1):1-21 PubMed PMID: 17574959
PMID 17574959
 
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26
Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H
2)/t(3;3)(q21;q26 2) and various other 3q abnormalities in acute myeloid leukemia
PMID 20660833
 
Cytogenetic profile of myelodysplastic syndromes with complex karyotypes: an analysis using spectral karyotyping
Martínez-Ramírez A, Urioste M, Alvarez S, Vizmanos JL, Calasanz MJ, Cigudosa JC, Benítez J
Cancer Genet Cytogenet 2004 Aug;153(1):39-47
PMID 15325092
 
Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients
Michels SD, Saumur J, Arthur DC, Robison LL, Brunning RD
Cancer 1989 Dec 1;64(11):2340-6
PMID 2804925
 
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA
J Clin Oncol 2002 Sep 15;20(18):3878-84
PMID 12228208
 
Chromosome study of 85 patients with myelodysplastic syndrome
Musilova J, Michalova K
Cancer Genet Cytogenet 1988 Jul 1;33(1):39-50
PMID 3164239
 
RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up
Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T, Ridge S, Carter G, White D, Oscier D, Chevret S, West R
Leukemia 1998 Jun;12(6):887-92
PMID 9639416
 
Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients
Pedersen B, Jensen IM
Leukemia 1991 Jul;5(7):566-73
PMID 2072742
 
Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization
Rücker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Fröhling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Döhner K, Döhner H
J Clin Oncol 2006 Aug 20;24(24):3887-94
PMID 16864856
 
Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia
Shurtleff SA, Meyers S, Hiebert SW, Raimondi SC, Head DR, Willman CL, Wolman S, Slovak ML, Carroll AJ, Behm F, et al
Blood 1995 Jun 15;85(12):3695-703
PMID 7780153
 
Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH
Van Limbergen H, Poppe B, Michaux L, Herens C, Brown J, Noens L, Berneman Z, De Bock R, De Paepe A, Speleman F
Genes Chromosomes Cancer 2002 Jan;33(1):60-72
PMID 11746988
 
Cytogenetics of chronic myelogenous leukemia (CML) correlated to the histopathology of bone marrow biopsies
Werner M, Kaloutsi V, Buhr T, Delventhal S, Vykoupil KF, Georgii A
Ann Hematol 1991 Oct;63(4):201-5
PMID 1932298
 
Trisomy 22 as the sole abnormality is an important marker for the diagnosis of acute myeloid leukemia with inversion 16
Xu W, Zhou HF, Fan L, Qian SX, Chen LJ, Qiu HR, Zhang SJ, Li JY
Onkologie 2008 Sep;31(8-9):440-4
PMID 18787351
 

Citation

This paper should be referenced as such :
Zamecnikova A
i(22)(q10) in myeloid malignancies;
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Anomalies/iso22qMyeloID1819.html


Translocations implicated (Data extracted from papers in the Atlas)

 i(22)(q10)

External links

Mitelman databasei(22)(q10) [Case List]    i(22)(q10) [Transloc-MCList]
arrayMap (UZH-SIB Zurich)Morph ( 9875/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMap (UZH-SIB Zurich)Morph ( 9983/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMap (UZH-SIB Zurich)Morph ( 9989/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMap (UZH-SIB Zurich)Morph ( 9874/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMap (UZH-SIB Zurich)Morph ( 9867/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMap (UZH-SIB Zurich)Morph ( 9891/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMap (UZH-SIB Zurich)Morph ( 9840/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMap (UZH-SIB Zurich)Morph ( 9861/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Nov 28 16:17:16 CET 2018


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.